Group 1 - PDD Holdings Inc. will report its unaudited financial results for the second quarter ended June 30, 2025, before U.S. markets open on August 25, 2025 [1] - The earnings conference call will take place at 7:30 AM ET on August 25, 2025 [1] - The conference call will be available for live webcast and replay on the company's investor website [2] Group 2 - PDD Holdings is a multinational commerce group that operates a portfolio of businesses aimed at integrating more businesses and individuals into the digital economy [3] - The company's mission is to enhance productivity and create new opportunities for local communities and small businesses [3]

Core Points - DallasNews Corporation is proposing a merger with Hearst, offering shareholders an all-cash consideration of $15 per share, which represents a 242% premium over the closing price of $4.39 on July 9, 2025 [1][4][8] - The Board of Directors unanimously supports the merger, emphasizing its potential to provide immediate liquidity and eliminate ownership risks for shareholders [2][4][7] - Shareholders are encouraged to vote "FOR" the merger at the special meeting scheduled for September 23, 2025, to secure the proposed cash premium [1][19][20] Company Overview - DallasNews Corporation is the holding company for The Dallas Morning News and Medium Giant, known for its strong journalistic reputation and community ties [20] - The Dallas Morning News has received nine Pulitzer Prizes, highlighting its commitment to quality journalism [20] - Medium Giant is recognized for its marketing excellence, having won several industry awards in 2024 [20] Merger Details - The merger with Hearst is positioned as a significant opportunity for DallasNews shareholders to realize immediate value and avoid market risks associated with public company ownership [7][12] - Hearst's offer is backed by its strong reputation in the media industry and financial capacity, providing assurance for the completion of the transaction [8][9] - The merger proposal requires approval from shareholders, with a two-thirds majority needed from both Series A and Series B Common Stock [19] Shareholder Communication - The Board has communicated the importance of the merger to shareholders, highlighting the risks of remaining a standalone public company if the merger is not approved [11][12] - DallasNews' largest shareholder, Mr. Robert W. Decherd, has publicly expressed his support for the merger and his commitment to preserving the legacy of DallasNews [10][13] - Shareholders are advised to disregard any competing proposals, particularly from Alden Global Capital, which has a controversial history in the newspaper industry [14][15][16]

Core Insights - Plus Therapeutics, Inc. announced positive data from the ReSPECT-LM Phase 1 trial, demonstrating a clinical benefit rate of over 75% in three relevant outcome measures for the treatment of leptomeningeal metastases with REYOBIQ [1][2] - The trial showed no dose-limiting toxicities and an overall favorable safety profile, indicating the treatment is feasible and effective [1][4] Study Details - The Phase 1 trial involved 29 subjects across six cohorts receiving varying doses of REYOBIQ, ranging from 6.6 mCi to 75 mCi [2] - Early cohorts exhibited excellent tolerance at higher doses, supporting a broad therapeutic range [4] Efficacy and Safety - The study reported a radiographic response rate of 76% and a clinical response rate of 87% through day 112 [6] - CSF tumor cell enumeration assays showed a maximum reduction of 100% at day 28, with a median overall survival of 9 months across the first four cohorts, which is significantly better than the typical 2-6 months reported in literature [6] Future Directions - The trial results provide a foundation for moving into ongoing dosing optimization and potential approval trials [4] - REYOBIQ is being evaluated for multiple CNS cancers, including recurrent glioblastoma and pediatric brain cancer, with significant funding support from the National Cancer Institute and the Cancer Prevention & Research Institute of Texas [5][7]

Company Overview - OneMedNet Corporation is a leader in AI-powered Real-World Data (RWD) and has established a long-term strategic partnership with Circle Cardiovascular Imaging Inc. to enhance cardiac diagnostics and treatment planning [1][4] - Circle CVI selected OneMedNet's iRWD™ platform for access to diverse and regulatory-grade cardiovascular datasets, which includes data from over 1,750 provider sites and over 131 million exams [2][4] Partnership Details - The collaboration allows Circle CVI to expand its research and development capabilities while aligning with evolving regulatory and clinical evidence standards [4] - Circle CVI's CEO highlighted the exceptional quality and regulatory readiness of OneMedNet's data, indicating a commitment to a long-term partnership [3][5] Industry Implications - This partnership exemplifies a growing industry shift towards utilizing real-world evidence as a foundation for medical innovation [4] - OneMedNet's platform is positioned to revolutionize how healthcare companies access and utilize Real-World Data, which is critical for driving innovation in various medical fields [5]

Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak’s initial non-binding proposal.Board unanimously recommends shareholders vote “FOR” the Arrangement.Shareholders are encouraged to review the circular carefully ...

Series RIKV 25 1119RIKV 26 0318Settlement Date 08/20/202508/20/2025Total Amount Allocated (MM) 16,08819,800All Bids Awarded At (Price / Simple interest) 98.096/7.67995.728/7.650Total Number of Bids Received 1820Total Amount of All Bids Received (MM) 18,18825,800Total Number of Successful Bids <td colspan="3" style="border-right: solid black 1pt ; border-left: solid black 1 ...

TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to announce promising results from a program of metallurgical testing undertaken in collaboration with Dundee Sustainable Technologies (“DST”), a subsidiary of Dundee Corporation (TSX: DC.A), to evaluate the effectiveness of DST’s Glasslock Process™ on a high-grade sample from the Joss deposit at the Company’s Beartrack-Arnett Gold Project (“Beartrack-Arnett” or, the “Project”) ...

TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) announced the appointment of Jane Skoblo as a director of the Company effective August 13, 2025. Ms. Skoblo will serve on both the Audit and Compensation & Organizational Development Committees of Mattr. Ms. Skoblo’s addition to the Board allows for an orderly transition as Laura Cillis, current Director and Audit Committee Chair, intends to retire from the Board at the Company’s next Annual General Meeting. Ms. Sk ...

TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Allied Properties Real Estate Investment Trust ("Allied") (TSX: "AP.UN") today provided an update with respect to pending completion of the final two ground-up developments in its development pipeline: M4 of Main Alley Campus, 108 East Fifth Avenue in Vancouver; and KING Toronto, 489-539 King Street West in Toronto. “Completing the large, multi-city development pipeline we initiated in 2012 has materially enhanced our ability to serve knowledge-based organizations, ...

Thom Lachman and Susan Panuccio Nominated as Independent Non-Executive Directors of the Company Event Registration Available Online at shareholdermeeting.howardhughes.com THE WOODLANDS, Texas, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Howard Hughes Holdings (NYSE: HHH) announced today that the company’s Annual Shareholder Meeting will take place on Tuesday, September 30 in New York City. HHH Executive Chairman Bill Ackman and Chief Investment Officer Ryan Israel will discuss the company’s plans to acquire an insura ...